Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Opdivo sales drive double-digit growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb

3Q Revenues: $4.9 billion (+21%)

3Q Earnings: $1.2 billion (+66%)

YTD Revenues: $12.9 billion (+16%)

YTD Earnings: $3.6 billion (+98%)

Comments: U.S. revenues increased 36% to $2.8 billion in the quarter and international revenues increased 5%.  Opdivo sales were $920 million in the quarter, up from $305 million 3Q15.Eliquis sales were up 90% to $84 million; Yervoy sales were up 19% to $285 million; Orencia sales grew 18% to $572 million; and Sprycel sales were up 15% to $472 million.The company’s virology product sales were down in the quarter. Baraclude sales were down 4% to $306 million; Hepatitis C Franchise sales were down 6% to $379 million; Reyataz sales were down 12% to $238 million; and Sustiva sales were 275 million, down 17%. Erbitux and Abilify are now trademarks of ImClone LLC and Otsuka Pharmaceutical Co., Ltd., respectively. Research and development expenses increased 1% to $1.1 billion in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters